Infant Microbiome: Vaginal Delivery Versus C-Section

A new literature review finds that even if babies born via Cesarean section have long-term health risks, as a number of past studies purport, it may not be a result of the procedure itself.

Written byJef Akst
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, MENNONITE CHURCH USA ARCHIVESSeveral studies in the last five years have found that babies born via C-section tend to have altered microbiomes and face more health risks than babies born vaginally. But in some analyses of infant microbiomes, researchers failed to take into consideration the underlying reasons why a Cesarean section was performed, researchers reported in a review article published last week (November 24) in EMBO Reports. This suggests that “exposures and events throughout pregnancy that may ultimately result in a Cesarean or follow thereafter—but not the surgery itself—may be the true drivers of variation in the microbiome and risk of atopic disease, obesity, or metabolic disorders later in life,” the authors wrote.

Moreover, a closer look at prior studies investigating microbiome differences between infants delivered vaginally and via C-section revealed varying results. “When we dug into the literature in greater detail, we found that other investigators were not seeing a strong difference in the early microbiomes of Cesarean and vaginally delivered infants,” coauthor Kjersti Aagaard, a maternal-fetal medicine specialist of Baylor College of Medicine and Texas Children’s Hospital, said in a press release. “In fact, the data appeared to be pretty mixed. While some small studies showed a difference, other larger studies did not.”

The findings draw into question prior work, which has suggested that birth mode (as opposed to the circumstances leading up to birth) significantly impacts the early-life microbiome and risk of noncommunicable diseases such ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies